Completed OBSERVATIONAL NCT04894214

Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 (VICAR)

Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 - an Interventional Cross-over Study

Sponsor: University Hospital, Antwerp

Conditions COVID-19 Acute Respiratory Distress Syndrome Respiration, Artificial

Interventions Arterial blood gas (ABG) Recording of hemodynamic monitoring Recording of respiratory monitoring

Updated 5 times since 2021 Last updated: Feb 2, 2022 Started: Jan 11, 2021 Primary completion: Apr 23, 2021 Completion: May 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04894214, this observational or N/A phase trial focuses on COVID-19 Acute Respiratory Distress Syndrome and Respiration, Artificial and remains completed. Sponsored by University Hospital, Antwerp, it has been updated 5 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Mar 2022 — Jul 2024 [monthly]

Completed

Status: Active Not Recruiting → Completed
Dec 2021 — Mar 2022 [monthly]

Active Not Recruiting
Jun 2021 — Dec 2021 [monthly]

Active Not Recruiting

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Antwerp

Data source: University Hospital, Antwerp

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edegem, Belgium